相关实验视频

Updated: Jun 15, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

多发性骨髓瘤中的BCMA CAR-T细胞准备起飞?

Lukas Scheller^1,2, Erius Tebuka^3,4, Peter Fabian Rambau³

¹Medizinische Klinik und Poliklinik II und Lehrstuhl für zelluläre Immuntherapie, Medizinische Klinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Leukemia & lymphoma

|November 24, 2023

概括

针对B细胞成熟抗原 (BCMA) 的化学抗原受体T细胞 (CAR-T) 疗法显示出治疗多发性骨髓瘤的前景. 本审查涵盖已批准的CAR-T产品,试验和克服治疗挑战的策略.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

多发性骨髓瘤 (MM) 仍然在很大程度上无法治愈,尽管新药获得批准.
免疫治疗的最新进展,特别是CAR-T疗法,为MM患者提供了新的希望.

研究的目的:

审查已批准的BCMA指导的CAR-T产品和MM正在进行的临床试验.
探索增强BCMA导向CAR-T疗效和克服治疗失败的策略.
讨论MM的CAR-T治疗的副作用和全球可访问性.

主要方法:

审查目前已批准的BCMA导向CAR-T疗法.
对正在进行的多发性骨髓瘤临床试验的分析.
探索改善CAR-T疗法的创新方法.

主要成果:

由于BCMA在血细胞上的表达,BCMA是MM中CAR-T治疗的高度特异性标.
在重度预治疗,复发/耐药MM患者中,CAR-T疗法显示出了显著的结果.

结论:

以BCMA指导的CAR-T疗法代表了MM治疗的重大进步,为治愈提供了潜在的机会.
需要进一步的研究来提高CAR-T的疗效,管理副作用,并改善全球可访问性.

关键词:

这就是为什么BCMABCMABCMA.在CART-T中,我们可以使用CAR-T.仿真抗原受体T细胞的T细胞受体临床试验是指临床试验中的临床试验.多发性骨髓瘤是多发性骨髓瘤的一种.

更多相关视频

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.